Compare Natera Inc. Common Stock (NTRA) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Wipro Limited — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Wipro Limited trades at $1.79 (market cap $17.45B). The key difference: Natera Inc. Common Stock is far larger — about 3.3× Wipro Limited's market cap, and Wipro Limited pays a 4.82% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Wipro Limited for 41 Days on average.
| NTRA | WIT | |
|---|---|---|
Market Cap | $57.03B | $17.45B |
Volume | 1,131,157 | 12,096,194 |
Sector | Health | Technology |
52-Week High | $425.64 | $3.06 |
52-Week Low | $179.42 | $1.61 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $56.18B | $15.54B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Wipro (WIT) trades at $1.80, up 5.88% with a bullish technical signal. The company maintains solid fundamentals with $890.88B revenue, 13.92% net margin, and $131.35B net income for 2025. Recent AI initiatives have boosted productivity equivalent to 20,000 employees. However, the stock faces mixed analyst sentiment with only 19% buy ratings and recent earnings misses.
Wipro presents a mixed investment case with reasonable valuation (P/E 13.84) and strong cash flow generation offset by earnings volatility and competitive pressures. The AI transformation offers growth potential, but investors should weigh execution risks against the company's established market position and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
